Search research articles
Contact Us
Filters
Showing results (41-50 of 99) with videos related to
Page
of 10
Sort By:
Cancers
|
October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma
Aimaz Afrough, Shebli Atrash, Barry Paul, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 9, 2021
Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review
Hamid Ehsan, Abdul Rafae, Adeel Masood, et al.
Hematology/Oncology and Stem Cell Therapy
|
May 16, 2020
Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis
Hamza Hashmi, Shruti Bhandari, Rohit Kumar, et al.
Transplantation and Cellular Therapy
|
January 22, 2023
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma
Hamza Hashmi, Shebli Atrash, Jayanshu Jain, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 18, 2025
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure
Prerna Mewawalla, Rachel Dileo, Yue Yin, et al.
Annals of Hematology
|
July 28, 2021
Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature
Zoia Ehsan Khattak, Hamza Hashmi, Sana Irfan Khan, et al.
Transplantation and Cellular Therapy
|
February 22, 2023
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience
Aswani Thurlapati, Kiera Roubal, James A Davis, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 16, 2024
Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
Bruno Almeida Costa, Thomaz Alexandre Costa, Gabriel Cavalcante Lima Chagas, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 1, 2022
Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy
James A Davis, Kelly J Gaffney, Mary McGann, et al.
Transplantation and Cellular Therapy
|
December 24, 2023
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
James A Davis, Danai Dima, Nausheen Ahmed, et al.
Page
of 10
Search research articles
Search
Showing results (41-50 of 99) with videos related to
Sort By:
Page
of 10
Cancers
|
October 14, 2023
Efficacy and Safety of Daratumumab, Pomalidomide, and Dexamethasone (DPd) Compared to Daratumumab, Bortezomib, and Dexamethasone (DVd) in Daratumumab-Naïve Relapsed Multiple Myeloma
Aimaz Afrough, Shebli Atrash, Barry Paul, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
December 9, 2021
Efficacy and Safety of Daratumumab-based Regimens in Pretreated Light Chain (AL) Amyloidosis: A Systematic Review
Hamid Ehsan, Abdul Rafae, Adeel Masood, et al.
Hematology/Oncology and Stem Cell Therapy
|
May 16, 2020
Twice-daily intravenous bolus tacrolimus infusion: A safe and effective regimen for graft-versus-host disease prophylaxis
Hamza Hashmi, Shruti Bhandari, Rohit Kumar, et al.
Transplantation and Cellular Therapy
|
January 22, 2023
Daratumumab, pomalidomide, and dexamethasone (DPd) followed by high dose chemotherapy-Autologous Stem Cell Transplantation leads to superior outcomes when compared to DPd-alone for patients with Relapsed Refractory Multiple Myeloma
Hamza Hashmi, Shebli Atrash, Jayanshu Jain, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
July 18, 2025
Real-World Outcomes of Sequential BCMA-directed therapies in Relapsed Refractory Multiple Myeloma After Belantamab Exposure
Prerna Mewawalla, Rachel Dileo, Yue Yin, et al.
Annals of Hematology
|
July 28, 2021
Dawn of a new era of antibody-drug conjugates and bispecific T-cell engagers for treatment of multiple myeloma: a systematic review of literature
Zoia Ehsan Khattak, Hamza Hashmi, Sana Irfan Khan, et al.
Transplantation and Cellular Therapy
|
February 22, 2023
Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience
Aswani Thurlapati, Kiera Roubal, James A Davis, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
October 16, 2024
Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials
Bruno Almeida Costa, Thomaz Alexandre Costa, Gabriel Cavalcante Lima Chagas, et al.
Clinical Lymphoma, Myeloma & Leukemia
|
November 1, 2022
Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy
James A Davis, Kelly J Gaffney, Mary McGann, et al.
Transplantation and Cellular Therapy
|
December 24, 2023
Impact of Frailty on Outcomes after Chimeric Antigen Receptor T Cell Therapy for Patients with Relapsed/Refractory Multiple Myeloma
James A Davis, Danai Dima, Nausheen Ahmed, et al.
Page
of 10